Best Peptides for Low Libido in Women & HSDD: Evidence (2026)

Bremelanotide (PT-141), marketed as Vyleesi, is the only peptide with proven, FDA-approved efficacy for female low libido. It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone that non-selectively activates central melanocortin receptors, predominantly MC4R, in hypothalamic and limbic circuits implicated in sexual desire and arousal — so it targets the brain rather than the bloodstream, unlike the PDE5 inhibitors used for male erectile function. The FDA approved it on June 21, 2019 for premenopausal women with acquired, generalized HSDD, based on two identical 24-week, randomized, double-blind, placebo-controlled Phase 3 trials (RECONNECT; Studies 301/302, NCT02333071 and NCT02338960) enrolling 1,247 premenopausal women. Versus placebo, bremelanotide produced statistically significant increases in sexual desire and significant reductions in desire-related distress (both P < 0.001), and a 52-week open-label extension showed sustained improvement with no new safety signals. The honest read on effect size, though, is that the benefit is modest: the co-primary endpoints moved roughly a half-point on the desire scale and about 0.7 points on the desire-related distress item, and notably the trials did not show a significant increase in the number of satisfying sexual events on the primary analysis. It is dosed on demand — 1.75 mg subcutaneously via autoinjector about 45 minutes before anticipated activity, no more than once per 24 hours and no more than 8 doses per month. Nausea (~40%), flushing and headache are common, and it is contraindicated in uncontrolled hypertension or known cardiovascular disease.

Best for

Premenopausal women with acquired, generalized HSDD after a root-cause workup — as an FDA-approved, as-needed tool for a specific phenotype, not a libido cure

Pricing

Varies by pharmacy

Source: Kingsberg SA, Clayton AH et al., Obstet Gynecol 2019 (RECONNECT, n=1,247)

Kisspeptin is the master upstream regulator of the reproductive hormonal axis, but it also has direct neuromodulatory effects on limbic sexual and attraction circuits independent of downstream hormones — which is why it is genuinely interesting for female desire rather than just fertility. In a randomized, double-masked, placebo-controlled, two-way crossover trial, 40 premenopausal women with HSDD (32 completers) received a 75-minute intravenous infusion of kisspeptin-54 (1 nmol/kg/h) versus placebo. Kisspeptin modulated sexual and facial-attraction brain processing on functional MRI — for example, deactivation of the left inferior frontal gyrus (Z max 3.76, P = .01) and activation of the right postcentral/supramarginal gyrus (Z max 3.73, P < .001) — and those brain changes correlated with psychometric measures of sexual aversion and distress. A companion trial in men with HSDD found kisspeptin increased sexuality-related brain activity and augmented penile tumescence by up to about 56% over placebo (P = .002), reinforcing a genuine central effect across sexes. The honest gap, though, is decisive: these are proof-of-mechanism studies measuring neuroimaging and questionnaires after a single short infusion — not sustained real-world outcomes such as satisfying sexual events over weeks. Kisspeptin was well tolerated as short research infusions, but there is no approved product, no established take-home regimen, and no Phase 3 efficacy data for desire. Kisspeptin-54 has separately been studied as an IVF trigger, relevant to its biology and safety but not to libido efficacy. There is no validated outpatient 'kisspeptin-10' libido protocol; products sold that way are unproven extrapolations.

Best for

Following the most promising emerging science on female desire — as investigational research, not as an available treatment

Pricing

Not commercially validated

Source: Comninos AN, Thurston L et al., JAMA Network Open 2022 (women with HSDD RCT)

Oxytocin is released during arousal, orgasm and lactation and is associated with attachment and orgasm intensity, which is the theoretical basis for trying it in female sexual dysfunction — and it is heavily marketed on that plausible story. The evidence, however, does not support it for desire. The most rigorous trial was a randomized, double-blind, placebo-controlled crossover study of on-demand intranasal oxytocin (32 IU) versus placebo in 30 pre- and postmenopausal women with sexual dysfunction: both oxytocin and placebo improved Female Sexual Function Index and distress scores, with no statistically significant treatment, sequence, or interaction effect. In other words, oxytocin did not beat placebo — a textbook placebo signal in female sexual dysfunction, and exactly why the placebo response must stay front and center when reading this field. Smaller acute studies have reported subjective increases in orgasm intensity and contentment, but these are not robust controlled desire-efficacy data and are heavily confounded by expectation. Intravaginal oxytocin formulations have mainly been trialed for breastfeeding-related dyspareunia, a different problem than low desire. An ongoing trial is testing acute intranasal oxytocin on sexual well-being in a specific population (AVP deficiency), underscoring that the question is open rather than settled — but for the specific claim that oxytocin reliably raises female desire, the best controlled evidence is negative. Short-term intranasal oxytocin is generally well tolerated, though it can exert sympathomimetic and chronotropic effects in controlled settings; given the negative primary efficacy data, the risk-to-evidence ratio for using it to raise desire is unfavorable.

Best for

Understanding why a plausible, popular mechanism is not the same as proven efficacy — a cautionary example, not a desire treatment

Pricing

Varies; not validated for desire

Source: Muin DA et al., Fertil Steril 2015 (crossover RCT, negative for desire)

This entry exists to name the marketing pattern honestly, because 'research use only' PT-141 and compounded/research kisspeptin and oxytocin are what most consumers actually encounter — sold on the borrowed credibility of the studies above. 'Research-grade' PT-141 is chemically the same molecule as Vyleesi, but that is not equivalence: research-chemical product is not manufactured to pharmaceutical standards, not quality-controlled, and not approved for human use, and vials can carry contaminants and inaccurate dosing. Compounded bremelanotide can be dispensed by a 503A pharmacy on a patient-specific prescription, but it still lacks FDA-approved-product oversight. Compounded 'kisspeptin-10' libido protocols are unvalidated extrapolations from a single IV kisspeptin-54 mechanistic study — a different fragment, a different half-life, a different route, and no controlled desire-efficacy data. Oxytocin sold for libido is marketed despite the best controlled trial being negative. All of these occupy a legal gray area, are not approved for human use, and importation can trigger customs and quality risks; the FDA has acted against vendors marketing such products for human use. For athletes, bremelanotide is not listed by name on the 2026 WADA Prohibited List, but WADA's peptide-hormone sections carry broad catch-all language, so tested athletes should consult their anti-doping authority first. We rank this last and grade it X — genuinely unclear, not preliminarily positive — because same-molecule marketing without approved-product oversight or condition-specific efficacy data is exactly the pattern that misleads consumers.

Best for

Recognizing the gap between same-molecule marketing and evidence — the consumer forms lack approved-product oversight and condition-specific proof

Pricing

Not a validated product

Source: The Peptide Guides, Peptide Legality & FDA Status Guide (2026)

Kisspeptin-10 is the shorter C-terminal decapeptide — the form usually marketed and compounded for consumers — and it is listed separately here precisely because it is routinely confused with the kisspeptin-54 that generated the only human female-desire signal. Kisspeptin-10 shares the same receptor (KISS1R) and core reproductive-endocrine bioactivity, but it has a much shorter half-life and, critically, was not the molecule tested in the HSDD brain-imaging RCT. The one randomized study in women with HSDD used a 75-minute intravenous infusion of kisspeptin-54 at 1 nmol/kg/h in a research setting; there is no validated outpatient kisspeptin-10 libido protocol, and the subcutaneous kisspeptin-10 products sold commercially are extrapolations from that kisspeptin-54 infusion work and from reproductive-hormone studies — not from any female-desire efficacy trial. That extrapolation is an unproven leap across three dimensions at once: a different molecule, a different pharmacokinetic profile, and a different route. Consequently the consumer kisspeptin-10 form has no controlled desire-efficacy data and should be regarded as grade X — genuinely unclear, not preliminarily positive — for any low-libido claim until it is actually tested in women. We rank it last because a same-family molecule with a plausible receptor rationale but zero controlled desire data, marketed on the borrowed credibility of a different peptide's single mechanistic study, is exactly the pattern that misleads consumers. Anyone interested in the kisspeptin mechanism for female desire should follow the kisspeptin-54 research, not assume the marketed decapeptide inherits its brain-imaging results.

Best for

Recognizing the gap between marketing claims and evidence — the consumer decapeptide has no controlled female-desire data

Pricing

Varies; not validated for desire

Source: Comninos AN, Thurston L et al., JAMA Network Open 2022 (used kisspeptin-54, not -10)